122 related articles for article (PubMed ID: 10435938)
1. Raloxifene as a multifunctional medicine? Current trials will show whether it is effective in both osteoporosis and breast cancer.
Jordan VC; Morrow M
BMJ; 1999 Aug; 319(7206):331-2. PubMed ID: 10435938
[No Abstract] [Full Text] [Related]
2. [Estrogen agonists, especially raloxifene, in the treatment of osteoporosis].
Lips P; Netelenbos JC
Ned Tijdschr Geneeskd; 1996 Jun; 140(23):1215-7. PubMed ID: 8700270
[No Abstract] [Full Text] [Related]
3. Estrogen receptor as a target for the prevention of breast cancer.
Jordan VC
J Lab Clin Med; 1999 May; 133(5):408-14. PubMed ID: 10235123
[No Abstract] [Full Text] [Related]
4. Patterns of physician-reported diagnoses for women receiving raloxifene prescriptions.
Ohsfeldt RL; O'Connor LJ; Kemner JE; Solomon TE
Am J Health Syst Pharm; 2001 Oct; 58(19):1846-9. PubMed ID: 11596702
[No Abstract] [Full Text] [Related]
5. Osteoporosis drugs show early promise.
Rackoff P
Lancet; 1997 Jun; 349(9067):1748. PubMed ID: 9213711
[No Abstract] [Full Text] [Related]
6. Raloxifene provides an alternative for osteoporosis prevention.
Willhite SL; Goebel SR; Scoggin JA
Ann Pharmacother; 1998; 32(7-8):834-7. PubMed ID: 9681100
[No Abstract] [Full Text] [Related]
7. Phase II evaluation of Ly156758 in metastatic breast cancer.
Buzdar AU; Marcus C; Holmes F; Hug V; Hortobagyi G
Oncology; 1988; 45(5):344-5. PubMed ID: 3412740
[TBL] [Abstract][Full Text] [Related]
8. [Raloxifene: a new molecule for the prevention of menopausal osteoporosis].
Oliaro A
Minerva Ginecol; 1998 Mar; 50(3):XII-XIII. PubMed ID: 9595915
[No Abstract] [Full Text] [Related]
9. Designer estrogens: breast cancer benefit, remaining questions.
Health News; 1999 Jul; 5(9):6. PubMed ID: 10480007
[No Abstract] [Full Text] [Related]
10. New hope for prevention, treatment of breast cancer.
Harv Health Lett; 1998 Aug; 23(10):6-7. PubMed ID: 9723013
[No Abstract] [Full Text] [Related]
11. Molecular biology of the estrogen receptor aids in the understanding of tamoxifen resistance and breast cancer prevention with raloxifene.
Jordan VC
Recent Results Cancer Res; 1998; 152():265-76. PubMed ID: 9928564
[No Abstract] [Full Text] [Related]
12. Tamoxifen, raloxifene findings unlikely to encourage genetic screening for breast cancer.
Dove A
Nat Med; 1998 Jun; 4(6):647. PubMed ID: 9623955
[No Abstract] [Full Text] [Related]
13. Breast cancer highlights.
Kuter I
Oncologist; 1999; 4(4):299-308. PubMed ID: 10476541
[No Abstract] [Full Text] [Related]
14. Raloxifene approval ushers in new drug class for osteoporosis. Estrogen-receptor effects vary by tissue type.
Am J Health Syst Pharm; 1998 Jan; 55(2):104. PubMed ID: 9465969
[No Abstract] [Full Text] [Related]
15. Raloxifene, retinoids, and lavender: "me too" tamoxifen alternatives under study.
Ziegler J
J Natl Cancer Inst; 1996 Aug; 88(16):1100-2. PubMed ID: 8757185
[No Abstract] [Full Text] [Related]
16. Current controversies in breast cancer management.
Morrow M; Jordan VC; Takei H; Gradishar WJ; Pierce LJ
Curr Probl Surg; 1999 Mar; 36(3):163-216. PubMed ID: 10089889
[No Abstract] [Full Text] [Related]
17. Raloxifene examined for breast cancer prevention.
Young D
Am J Health Syst Pharm; 2007 Sep; 64(17):1774. PubMed ID: 17724350
[No Abstract] [Full Text] [Related]
18. [Agonists-antagonists of estrogens, their potential use in prophylaxis and treatment of osteoporosis].
Hoszowski K
Pol Tyg Lek; 1995 Nov; 50(44-47):41-2. PubMed ID: 8643425
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen, raloxifene, and the prevention of breast cancer.
Jordan VC; Morrow M
Endocr Rev; 1999 Jun; 20(3):253-78. PubMed ID: 10368771
[No Abstract] [Full Text] [Related]
20. Raloxifene.
Balfour JA; Goa KL
Drugs Aging; 1998 Apr; 12(4):335-41; discussion 342. PubMed ID: 9571395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
